Arctica Finance advisor to Oculis in a USD 100 million equity offering

14. February 2025

As announced today, Friday, the 14^th of February 2025, Oculis Holding AG (the "Company" or "Oculis") announced that it has completed an equity offering of USD 100 million. The offering was oversubscribed by both foreign and Icelandic investors.

Oculis intends to use the proceeds from the Offering to advance and accelerate its clinical development pipeline, particularly the development of its novel neuroprotective clinical candidate Privosegtor (OCS-05), as well as for working capital and general corporate purposes.

Arctica Finance acted as an advisor to Oculis in the offering and managed the offering to Icelandic investors. Other advisors in the offering were BofA Securities, Leerink Partners and Pareto Securities.